Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $949.59 MXN
Change Today 0.00 / 0.00%
Volume 305.0
As of 11:06 AM 08/3/15 All times are local (Market data is delayed by at least 15 minutes).

merck & co. inc. (MRK*) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/4/15 - $950.40
52 Week Low
08/5/14 - $711.55
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for MERCK & CO. INC. (MRK*)

merck & co. inc. (MRK*) Details

Merck & Co., Inc. provides health care solutions worldwide. The company offer therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases. It also offers neuromuscular blocking agents for use in surgery; anti-bacterial products for skin and skin structure infections; antidepressants; ophthalmic and cholesterol modification products; non-sedating antihistamine; and vaginal contraceptive implants. In addition, the company provides products to prevent chemotherapy-induced and post-operative nausea and vomiting; to treat brain tumors and melanoma; to prevent diseases caused by human papillomavirus, as well as vaccines for measles, mumps, rubella, varicella, chickenpox, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers animal health products, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics for, and vaccines against bacterial and viral disease in fish. Additionally, the company provides companion animal products, such as diabetes mellitus treatment drugs and vaccines for dogs and cats; ointments for acute and chronic otitis; anthelmintic products; chewable tablets to kill fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. The company serves drug wholesalers and retailers, hospitals, government entities and agencies, physicians, physician distributors, veterinarians, distributors, and animal producers, as well as managed health care providers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey. Merck & Co. Inc formerly operated as a subsidiary of Merck KGaA.

69,000 Employees
Last Reported Date: 07/28/15
Founded in 1891

merck & co. inc. (MRK*) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.5M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $3.2M
Executive Vice President and President of Mer...
Total Annual Compensation: $1.5M
President of Global Human Health and Executiv...
Total Annual Compensation: $962.4K
Compensation as of Fiscal Year 2014.

merck & co. inc. (MRK*) Key Developments

Allergan plc Enters into a Licensing Agreement with Merck & Co., Inc

Allergan plc entered into a licensing agreement with Merck & Co. Inc. to acquire the worldwide rights to Merck's investigational small molecule oral calcitonin gene-related peptide (CGRP) receptor antagonists, which are being developed for the treatment and prevention of migraine, subject to expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR). Under the terms of the agreement, Allergan will acquire these rights for an upfront payment of $250 million, $125 million of which is payable upon HSR clearance and $125 million of which is payable in April of 2016. Merck will additionally be entitled to receive potential development and commercial milestone payments and tiered double-digit royalties based on commercialization of the programs. Allergan will be responsible for development of the CGRP programs, as well as manufacturing and commercialization upon approval and launch of the products. The agreement gives Allergan rights to two CGRP receptor antagonists: MK-1602, an oral small molecule antagonist for the acute treatment of migraines, and MK-8031, an oral small molecule antagonist for the prevention of migraines. The partnership will allow Allergan to strengthen its pipeline of central nervous system (CNS) development products.

Merck Announces Phase 3 Study of Single-Dose EMEND (fosaprepitant dimeglumine) for Injection Regimen Met Primary Endpoint in Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy

Merck announced results from a Phase 3 study investigating the safety and efficacy of single-dose EMEND (fosaprepitant dimeglumine) for Injection, Mercks substance P/neurokinin (NK-1) receptor antagonist, in combination with other anti-vomiting medicines, for the prevention of chemotherapy-induced nausea and vomiting (CINV) in adult cancer patients receiving moderately emetogenic (vomit-inducing) chemotherapy (MEC). In the study, the first to evaluate an intravenous NK-1 receptor antagonist for the prevention of CINV associated with MEC, the single-dose EMEND for Injection regimen provided greater protection from nausea and vomiting following administration of chemotherapy versus an active control of placebo with other anti-vomiting medicines. These data were presented in an oral session at the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) Annual Meeting on Supportive Care in Cancer (Abstract #27-02-O) in Copenhagen (June 25-27, 2015). EMEND for Injection, a substance P/Neurokinin-1 (NK1) receptor antagonist approved for use in combination with other antiemetic agents, is indicated in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer (HEC) chemotherapy, including high-dose cisplatin; and for prevention of nausea and vomiting associated with initial and repeat courses of MEC. EMEND has not been studied for treatment of established nausea and vomiting. Chronic continuous administration of EMEND is not recommended. In the U.S., the single-dose regimen of EMEND for Injection is approved for use associated with HEC. Merck plans to submit these recent data to the Food and Drug Administration in the second half of 2015 to seek approval for a regimen containing single-dose EMEND for Injection for the prevention of CINV associated with MEC.

Merck to Invest EUR 30 Million in New OLED Materials Production Plant in Darmstadt

Merck has announced that it will invest EUR 30 million in new OLED materials production plant in Darmstadt. Production of high-purity OLED materials for use in displays and lighting systems is scheduled to start in the approximately 2,000 square meter building in July 2016. Organic light-emitting diodes (OLEDs) are semiconducting organic materials which emit light and luminesce when electric voltage is applied. They are particularly suited for applications in the very latest generation of displays and lighting because they provide brilliant colors and sharp images from any viewing angle.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MRK*:MM $949.59 MXN 0.00

MRK* Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $150.12 USD -1.22
Amgen Inc $175.59 USD -1.00
Bayer AG €134.70 EUR +0.65
Gilead Sciences Inc $119.60 USD +1.74
GlaxoSmithKline PLC 1,400 GBp +4.00
View Industry Companies

Industry Analysis


Industry Average

Valuation MRK* Industry Range
Price/Earnings 17.2x
Price/Sales 4.2x
Price/Book 3.5x
Price/Cash Flow 16.9x
TEV/Sales 3.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MERCK & CO. INC., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at